How Many Fraxel Sessions Do You Need? A Clinic Buyer's Honest Take on Solta Medical Products

Most patients need three to five Fraxel sessions, spaced four to six weeks apart. If you're a patient, budget for the full series before you book the first one—not after. If you're a clinic owner evaluating Solta Medical products, plan your pricing and consumables budget around that same number, because treatment count drives everything else on the P&L. And if you're searching for Solta Medical stock, the short answer is: there isn't any. Solta has been part of Bausch Health (NYSE: BHC) since early 2014.

I come at this from the procurement side of the table. I've managed purchasing for a 20-person medical aesthetics clinic for six years, with an annual budget of roughly $420,000 across devices, consumables, and service contracts. I track every invoice in our cost system—a habit I developed after getting burned twice in year one (once by a "free setup" offer that turned into $450 in line-item fees, once by a service contract that didn't cover the part that actually broke). I've compared quotes from eight different laser and RF vendors in that time. Solta's devices—Thermage, Fraxel, Clear+Brilliant—have come up in every serious evaluation we've done.

The Fraxel session math: what patients should plan for

Here's how I translate the clinical literature into budget numbers, because that's my job. Fraxel Re:store (the 1550nm non-ablative fractional laser) is typically delivered as a series of three to five sessions for acne scarring, surgical scars, and general skin texture issues. Sessions run four to six weeks apart. Fine lines and early photoaging? Three sessions often does it. Stubborn melasma or deeper scars? Plan on five to six, and understand that maintenance touch-ups are part of the deal after the initial series is done.

The fully ablative version—Fraxel Repair, which uses a CO2 wavelength—is a different cost structure altogether. Most patients only need one session, maybe a touch-up at six to twelve months. But downtime is substantial (a week or more of visible recovery), and the per-session price is several times higher than Re:store from the patient's perspective and in what you can justify charging.

What's interesting from my perch: "how many Fraxel sessions do you need" is the question patients actually ask before booking, yet most marketing materials answer with a vague range. I suspect that's because the honest answer varies by skin condition, skin type, and tolerance for downtime. (A patient with mild photodamage and a patient with deep ice-pick scars are not buying the same treatment plan.) But "it depends" isn't a helpful search result, so here's my rule of thumb: expect three to five, book in single sessions until you've done at least two, and trust the clinician's assessment before extending the series.

What Solta Medical products actually cost a clinic

I'll say this plainly: the sticker price of the device is not the real expense. If you're building a total-cost-of-ownership model for any aesthetic clinic device—not just Solta—here's the framework I use:

• The device itself. Fraxel systems typically quote between $75,000 and $150,000 depending on model and configuration. Thermage FLX falls in a similar band. Don't anchor on those numbers though; regional pricing, bundles, and trade-in deals shift things a lot.
• Consumables. This is the line item that almost caught us. Fraxel and Thermage both require single-use tips per treatment. If you're running 15 Fraxel treatments a week, disposable tip costs run into the thousands per month—before you pay staff a cent. Negotiating these recurring costs at the time of purchase is critical, because they certainly don't go down after the contract is signed.
• Service contracts. Budget 8–12% of device cost per year for maintenance. That number sounds boring until a laser loses calibration in week three of a fully booked calendar.
• Training and ramp-up. New devices mean training hours where your RNs or physicians aren't generating revenue. We budget $4–8k per device for this, including the soft cost of shadow days.

The hidden gotcha: none of these costs matter if utilization is low. A $100,000 laser that runs three hours a week in a high-rent clinic is losing money, period. I've had that conversation with more clinic owners than I can count.

Thermage: the facial skin tightening piece

Thermage is Solta's flagship for non-invasive facial skin tightening. It's monopolar radiofrequency, FDA-cleared for skin tightening and smoothing, and one treatment can take 45 to 90 minutes with collagen remodeling continuing for months afterward. Prices to patients range from roughly $1,500 to $4,500 depending on treatment area and market.

Here's what I noticed from our booking data: Thermage's brand recognition is disproportionately high compared to other RF systems. This was true years ago and it's still true now. When patients research "facial skin tightening without surgery," they hit Thermage before most competitors. That search behavior translates to phone calls—I'd estimate 30% of our newer tightening consults mention Thermage by name.

Why brand matters more than I expected

As a cost controller, I'm constitutionally skeptical of brand premiums. But client data won me over. In Q2 2024, we surveyed new aesthetics patients about what influenced their choice of clinic. Sixty-eight percent said the device platforms offered mattered significantly—they'd Googled "aesthetic clinic device" and formed a preference before their consult. They weren't comparing price points between practices. They were comparing trust markers.

Patients weren't comparing price points between practices. They were comparing trust markers.

That changed my procurement calculus. A device with brand gravity is a marketing asset, not just a clinical tool. It's also why I've softened my stance on Solta's premium over lesser-known competitors: the prettiest spec sheet in the world doesn't make a patient think "this clinic seems legit." Frame it however you want—brand perception is either downstream of something real or it's a self-fulfilling prophecy. Either way, it affects bookings.

Solta Medical stock: a quick clarification

A lot of searches for "solta medical stock" are looking for a pure-play investment. There isn't one. Solta Medical was publicly traded until January 2014, when Valeant—now Bausch Health, NYSE: BHC—completed the acquisition. It operates as a subsidiary, so if you're evaluating the brand's financial trajectory, you're evaluating Bausch Health's overall portfolio, out of necessity. That's a corporate fact, not an investment recommendation. I'm a procurement guy, not an analyst. (Our CFO rolls his eyes when I mention investing.)

The underrated volume play: Clear+Brilliant

One more product worth a procurement note: Clear+Brilliant. It's Solta's gentler, lower-cost fractional laser (1927nm thulium). Patients pay a fraction of a Fraxel or Thermage price—usually $350–900 per session—and downtime is minimal. From a P&L standpoint, it's a volume driver and an on-ramp to higher-ticket treatments.

I'll be honest: I overlooked it for two years because it didn't generate the same per-treatment revenue. That was a mistake. Its positioning as a "maintenance" treatment gets patients through the door on a cycle that makes them eligible for Fraxel and Thermage down the line. If you're starting out and want Solta brand credibility at a lower entry cost, this is where I'd point a first-time buyer.

When Solta doesn't make sense

I want to be honest about the limits of this defense, because procurement people should be suspicious of one-sided recommendations.

• Low utilization risk. If you can't guarantee eight-plus treatment hours per device per week, the TCO math doesn't work. A cheaper device with different brand positioning starts to look rational.
• Discount-market positioning. If your average treatment ticket is under $350, Fraxel and Thermage economics won't support themselves—the consumable tip cost alone eats a meaningful chunk of revenue.
• Different clinical focus. If your practice is mostly body contouring or injectables, a laser/RF platform might be a distraction rather than a growth pillar.

For patients, my advice is similar to what I'd tell our own front desk: don't buy a full Fraxel package on the first visit. The three-to-five-session range is genuinely variable by skin response, and a reputable provider will recommend the next step after seeing how your skin reacts to the first sessions. (If someone pressures you into a six-session non-refundable package before any treatment, that's a red flag, not a bargain.)

There's also a compliance angle worth noting. Per FTC advertising guidelines (ftc.gov/business-guidance/advertising-marketing), claims about aesthetic treatment outcomes must be truthful, substantiated, and not misleading. That sounds obvious until you see competitors running "permanent results, guaranteed" content. We keep our marketing language tightly aligned with what the clinical data supports, because half-true promises create refund requests and bad reviews later.

The bottom line

Solta Medical products are premium tools for clinics that serve research-driven patients. If that's your market, the brand premium pays for itself in patient acquisition and closing rates. If it's not, the same premium is a cost you don't need.

As for the session question: three to five Fraxel treatments is the honest, typical answer. Build your budget, your marketing, and your expectations around that range. It's the same advice I'd give any patient walking into our clinic: know the full series cost before you start, and choose a provider who gives you the session count straight.

And if a vendor tells you their cheap alternative will deliver the same patient experience at half the device cost—ask for their TCO spreadsheet, consumables pricing, and a reference clinic you can call. I've made that call. (I inherited a "budget" device when I took this job that spent more time in the shop than in treatment rooms. We replaced it within two years.)